[go: up one dir, main page]

AR024537A1 - Combinacion sinergica para el tratamiento de enfermedades mediadas virales - Google Patents

Combinacion sinergica para el tratamiento de enfermedades mediadas virales

Info

Publication number
AR024537A1
AR024537A1 ARP000100819A ARP000100819A AR024537A1 AR 024537 A1 AR024537 A1 AR 024537A1 AR P000100819 A ARP000100819 A AR P000100819A AR P000100819 A ARP000100819 A AR P000100819A AR 024537 A1 AR024537 A1 AR 024537A1
Authority
AR
Argentina
Prior art keywords
mediumed
viral
diseases
treatment
synergic combination
Prior art date
Application number
ARP000100819A
Other languages
English (en)
Original Assignee
Inst Of Molecul & Cell Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Molecul & Cell Biology filed Critical Inst Of Molecul & Cell Biology
Publication of AR024537A1 publication Critical patent/AR024537A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las infecciones por falvivirus y rhabdovirus pueden ser tratadas administrando un interferon tal como el interferon a 2, el interferon a 8 o un interferonb y al menos un compuesto seleccionado de los nucleosidos cíclicos de 5 miembros, los compuestosmicofenolicos y los derivados de la imidazola,amidoadamantanos y 2,4-diaminopirimidinas.
ARP000100819A 1999-02-26 2000-02-25 Combinacion sinergica para el tratamiento de enfermedades mediadas virales AR024537A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12193199P 1999-02-26 1999-02-26
US18106800P 2000-02-08 2000-02-08

Publications (1)

Publication Number Publication Date
AR024537A1 true AR024537A1 (es) 2002-10-16

Family

ID=26819981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100819A AR024537A1 (es) 1999-02-26 2000-02-25 Combinacion sinergica para el tratamiento de enfermedades mediadas virales

Country Status (8)

Country Link
EP (1) EP1154787B1 (es)
AR (1) AR024537A1 (es)
AT (1) ATE301468T1 (es)
AU (1) AU3501100A (es)
CA (1) CA2362877A1 (es)
DE (1) DE60021857T2 (es)
MY (1) MY125300A (es)
WO (1) WO2000050064A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7408200A (en) * 1999-08-13 2001-03-13 F. Hoffmann-La Roche Ag Mycophenolate mofetil in association with peg-ifn-alpha
CA2400274A1 (en) * 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
JP2002201141A (ja) 2000-10-27 2002-07-16 Hayashibara Biochem Lab Inc 蛋白質合成抑制遺伝子の発現増強剤
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
CN115466710A (zh) * 2021-06-11 2022-12-13 舒泰神（北京）生物制药股份有限公司 一种获得无病毒细胞系的方法及其所获得的无病毒细胞系

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135898A (es) *
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
CA1317588C (en) * 1988-02-29 1993-05-11 Tohru Ueda Imidazole derivatives, process for production thereof, and use thereof
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
AU6037499A (en) * 1998-09-14 2000-04-03 Vertex Pharmaceuticals Incorporated Methods of treating viral disease

Also Published As

Publication number Publication date
CA2362877A1 (en) 2000-08-31
EP1154787B1 (en) 2005-08-10
EP1154787A2 (en) 2001-11-21
AU3501100A (en) 2000-09-14
ATE301468T1 (de) 2005-08-15
DE60021857T2 (de) 2006-06-01
MY125300A (en) 2006-07-31
DE60021857D1 (de) 2005-09-15
WO2000050064A3 (en) 2001-04-05
WO2000050064A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
UY28084A1 (es) Derivados antivirales de nucleosidos
DK1265889T3 (da) Lægemidler imod virussygdomme
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
ECSP077412A (es) Derivados de indol tetracíclicos como agentes antivíricos
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
PA8556901A1 (es) Nuevos derivados de piperazina
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
EA200000836A1 (ru) Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
DE60101223D1 (de) Antivirale pyrimidin nucleoside derivate
AR025929A1 (es) Compuestos para el tratamiento de enfermedades mediadas por virus
ES2108969T3 (es) Utilizacion de analogos de didesoxinucleosidos en el tratamiento de infecciones virales.
TW200633995A (en) Andrographolide derivatives to treat viral infections
AR024537A1 (es) Combinacion sinergica para el tratamiento de enfermedades mediadas virales